The area under the curve value for SPP1 was 0.893 (0.822-0.963) for the prediction of LC in patients with COPD. High expression of SPP1 in patients with LC was associated with shorter survival time. Up-regulation of SPP1 may be associated with increased risk of LC in patients with COPD and therefore may have potential as a therapeutic target for LC in patients with COPD. Patients with intestinal stoma would experience some periods of psychological disorders such as self-esteem disturbances. Self-esteem is one of the most important factors affecting the patient's mental health. It is suggested that factors such as emotional intelligence could be related to self-esteem. This study seeks to determine the correlation between emotional intelligence and self-esteem in patients with an ostomy. This was a descriptive-correlational study. This study was conducted on 155 patients with intestinal stoma referring to the selected hospitals affiliated to Iran University of Medical Sciences and Iranian Ostomy Association in 2018. The patients were selected using convenience sampling method. The study tools included demographic characteristics form, Rosenberg self-esteem scale and Schutte emotional intelligence questionnaire. Data analysis was performed in SPSS v.16 using descriptive and inferential statistics, including variance analysis and independent t test. Participants included 79 women and 76 men with the most frequency of age between 50-70years old. 52.26% of the cases had cancer and 45.81% of the cases had inflammatory bowel disease and other related diseases. Pearson correlation coefficient results showed a positive and significant correlation between total emotional intelligence and self-esteem (r=.56) (p=<.001).Participants included 79 women and 76 men with the most frequency of age between 50-70 years old. 52.26% of the cases had cancer and 45.81% of the cases had inflammatory bowel disease and other related diseases. Pearson correlation coefficient results showed a positive and significant correlation between total emotional intelligence and self-esteem (r = .56) (p = less then .001).Coronavirus disease 2019 (COVID-19) is a multisystemic disease that can cause progressive lung failure, organ dysfunction, and coagulation disorder associated with high mortality and morbidity. COVID-19 is known to either primarily cause skin symptoms or increase existing skin diseases. Human papillomavirus (HPV) is a DNA virus that can cause benign and malignant neoplasms. Mucocutaneous verruca vulgaris are common benign lesions of HPV. Here, we report a case of verruca vulgaris regressed after COVID-19. Immune checkpoint inhibitors improve survival in metastatic diseases for some cancers. Multisite SBRT with pembrolizumab (SBRT+Pembro) was shown to be safe with promising local control using biologically effective doses (BEDs)=95-120Gy. Increased BED may improve response rate; however, SBRT doses are limited by surrounding organs at risk (OARs). The purpose of this work was to develop and validate methods for safe delivery of ultra-high doses of radiation (BED >300) to be used in future clinical trials. The radiation plans from 15 patients enrolled on a phase I trial of SBRT+pembro were reanalyzed. Metastatic disease sites included liver (8/15), inguinal region (1/15), pelvis (2/15), lung (1/15), abdomen (1/15), spleen (1/15), and groin (1/15). EHT 1864 solubility dmso Gross tumor volumes (GTVs) ranged from 80 to 708cc. Following the same methodology used in the Phase I trial on which these patients were treated, GTVs>65cc were contracted to a 65cc subvolume (SubGTV) resulting in only a portion of the GTV receiving prescr VMAT planning approaches with clinical treatment planning software and linear accelerators prove capable of delivering radiation doses in excess of 360 Gy BED10 to tumor subvolumes, while maintaining safe OAR doses.In skin and wound research the instrumental measurement of skin function is established. Despite the widespread use, empirical evidence about measurement errors is widely lacking. The aim of this study was to measure reliability and agreement of skin temperature, transepidermal water loss, epidermal hydration, and erythema at the heel and sacral skin. Four experienced researchers performed skin measurements in 15 subjects. Lowest reliability was observed for transepidermal water loss at the sacral skin (ICC (1) 0.46 (95% CI 0.00-0.78)) and highest for skin temperature at the heel skin (ICC (1) 0.99 (95% CI 0.99-1.00)). Lowest Standard Errors of Measurement were calculated for skin temperature measurements at the heels (0.11°C) and highest for erythema measurements at the sacral skin (26.7 arbitrary units). There was a clear association between variability of estimates and reliability coefficients. Single measurements of skin temperature, stratum corneum, and epidermal hydration at the sacral and heel skin areas can be used in clinical research and practice. Means of at least two measurements should be used for estimating transepidermal water loss and erythema. Evidence is needed to inform researchers about relative and absolute measurement errors of commonly applied instruments and measurements in skin and wound research. Recent studies showed prolonged survival for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients treated with both monotherapies and combined therapies. However, high costs limit clinical applications. Thus, we conducted this cost-effectiveness analysis to explore an optimal first-line treatment for advanced EGFR-mutant NSCLC patients. Survival data were extracted from six clinical trials, including ARCHER1050 (dacomitinib vs. gefitinib); FLAURA (osimertinib vs. gefitinib/erlotinib); JO25567 and NEJ026 (bevacizumab +erlotinib vs. erlotinib); NEJ009 (gefitinib +chemotherapy vs. gefitinib); and NCT02148380 (gefitinib +chemotherapy vs. gefitinib vs. chemotherapy) trials. Cost-related data were obtained from hospitals and published literature. The effect parameter (quality-adjusted life year [QALY]) was the reflection of both survival and utility. Incremental cost-effectiveness ratio (ICER), average cost-effectiveness ratio (ACER), and net benefit were calculated, and the willingness-to-pay (WTP) threshold was set at $30828/QALY from the perspective of the Chinese healthcare system.